- MAR001 is a monoclonal antibody against angiopoietin-like protein 4 (ANGPTL4), an inhibitor of lipoprotein lipase.
- In Part A of the phase 2b trial, 235 adults with elevated triglycerides and remnant cholesterol received MAR001 300, 450, or 900 mg or placebo subcutaneously every 4 weeks for 24 weeks.
- In the primary analysis, placebo-adjusted changes in fasting triglycerides at week 12 were -39.1, -40.9, and -45.5 percentage points with the three doses (P<0.001 for all).
- Adverse events occurred in 69% of participants on MAR001 and 78% on placebo, and no participant had pancreatitis; LDL-C rose 7.4 to 10.5 percentage points relative to placebo.
In the phase 2b TYDAL-TIMI 78 trial, MAR001, a monoclonal antibody against ANGPTL4, lowered fasting triglycerides by 39.1 to 45.5 percentage points more than placebo at week 12 in participants with elevated triglycerides and remnant cholesterol. Michelle L. O’Donoghue, MD, MPH (Brigham and Women’s Hospital, Boston, MA), presented the Part A results at the American Heart Association (AHA) Scientific Sessions on November 9, 2026. They were published simultaneously in the New England Journal of Medicine
ANGPTL4 inhibits lipoprotein lipase, which breaks down circulating triglycerides. Carriers of ANGPTL4 loss-of-function variants have lower triglyceride levels and lower risks of diabetes and coronary disease, the investigators point out. ANGPTL4-deficient mice developed mesenteric inflammation on a high-fat diet, but MAR001 did not change mesenteric lymph node size or inflammation in an earlier phase 1b/2a study.
TYDAL-TIMI 78 (NCT07028749) was funded by Marea Therapeutics and designed by the TIMI Study Group. Seven of the 14 authors are affiliated with Marea. Part A enrolled adults aged 18 to 75 with fasting triglycerides of at least 150 mg/dL and remnant cholesterol of at least 30 mg/dL on confirmatory screening. Participants were randomized 1:1:1 to a dose group and then 3:1 to MAR001 or matching placebo every 4 weeks for 24 weeks. The primary endpoint was the placebo-adjusted percent change in fasting triglycerides at week 12, analyzed as prespecified in participants who remained on treatment.
Of 236 participants enrolled at 48 centers, 235 received study drug. Their mean age was 60.4 years, and 39% were women. Of the 235, 103 had type 2 diabetes and 170 were taking a statin. Median baseline fasting triglycerides were 249.5 mg/dL.
In the primary analysis, the placebo-adjusted change in fasting triglycerides at week 12 was -39.1 percentage points (95% CI -46.8 to -31.5) with 300 mg, -40.9 (95% CI -48.7 to -33.1) with 450 mg, and -45.5 with 900 mg (95% CI -53.2 to -37.8). All placebo-adjusted reductions were statistically significant (P< 0.001). Triglycerides fell 33.9% to 40.3% from baseline on MAR001 and rose 5.2% on placebo. An intention-to-treat sensitivity analysis yielded reductions of -39.1, -40.5, and -45.3 percentage points on the three doses. Through week 24, the placebo-adjusted changes were -32.0, -42.1, and -42.8 percentage points.
Fasting triglycerides fell below 150 mg/dL in 31%, 35%, and 52% of participants on the three doses and in 3% on placebo (P<0.001 for all). Placebo-adjusted fasting remnant cholesterol fell 37.3 to 40.8 percentage points at week 12, and non-fasting triglycerides fell 33.4 to 48.6 points at week 16. Among 73 participants with baseline triglycerides of at least 300 mg/dL, the placebo-adjusted reduction was 52.8 to 57.2 points.
Relative to placebo, HDL cholesterol rose 18.1 to 23.2 percentage points and LDL-C rose 7.4 to 10.5 points; the LDL-C confidence interval excluded zero only with 900 mg. Non-HDL cholesterol fell 8.2 to 10.8 points, and the confidence intervals for apolipoprotein B crossed zero.
Adverse events through week 24 occurred in 123 of 177 participants on MAR001 (69%) and 45 of 58 on placebo (78%). Serious adverse events occurred in 5 (3%) and 4 (7%), respectively, and injection-site reactions in 25 (14%) and 11 (19%), respectively. Diarrhea occurred in 7 of 60 participants (12%) on 900 mg. No participant had pancreatitis or died, and none on MAR001 had aminotransferase levels above three times the upper limit of normal. The investigators reported no adverse changes in markers of glucose homeostasis.
The results are limited to 24 weeks of treatment, and the trial was not powered to assess acute pancreatitis or cardiovascular events. Most participants were white (78% to 90% across groups), and few had severe hypertriglyceridemia.
The APOC3 inhibitors olezarsen and plozasiran lower triglycerides by about 60%, the investigators noted. Part B of the trial will test MAR001 600 mg every 4 weeks in patients with severe hypertriglyceridemia.
